Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors
about
Development and strategies of VEGFR-2/KDR inhibitors.Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach.Update on lymphocyte specific kinase inhibitors: a patent survey.Synthesis, Characterization and Anti-Cancer Activity of Hydrazide Derivatives Incorporating a Quinoline Moiety.Selective flexibility of side-chain residues improves VEGFR-2 docking score using AutoDock Vina.
P2860
Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@ast
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@en
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@nl
type
label
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@ast
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@en
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@nl
prefLabel
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@ast
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@en
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@nl
P2093
P356
P1476
Evaluation of a series of naph ...... r-2 tyrosine kinase inhibitors
@en
P2093
Alexander Long
Andrew Tasker
Angela Coxon
Anthony J Polverino
Charlie Starnes
Daniel S La
Danlin Chen
David Bauer
Deborah Choquette
Douglas A Whittington
P304
P356
10.1021/JM701098W
P407
P577
2008-03-27T00:00:00Z